Results from an open label clinical study, evaluating an oral daily dose of the drug enobosarm, shows promise for women with metastatic, androgen receptor positive, estrogen receptor positive breast cancer. The new data is from a phase 2 study reported on Monday, June 2, 2014 at the meeting in Chicago of the American Society of Clinical Oncology (ASCO).
READ FULL ARTICLE
From 170.223.191.243
Please login or register first to view this content.
Enjoying our content?
Thanks for visiting Oncology Nurse Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Oncology Nurse Advisor. Register for free and gain unlimited access to:
- Clinical Updates
- Evidence-Based Guidance
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Please login or register first to view this content.